GlassScriptPhysician profile
Sachida N Manocha
NPI 1821036435
$10,011.58
in general payments reported to CMS, 2019-2025
44 companies · $721 in 2025
The $721 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,190 · 2020: $755 · 2021: $2,412 · 2022: $2,414 · 2023: $1,360 · 2024: $1,159 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,211 · Travel and Lodging: $28.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,211.24 |
| Travel and Lodging | $28.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,719.48 | 2021-2025 | Synchromedii, Intellis Adaptivestim |
| Abbvie INC. | $1,429.12 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,298.61 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $758.93 | 2019-2025 | Xtampza, Belbuca |
| Supernus Pharmaceuticals, INC. | $514.24 | 2019-2022 | |
| Abbott Laboratories | $394.13 | 2019-2022 | |
| Medtronic USA, INC. | $379.70 | 2019-2020 | |
| Nevro Corp. | $362.53 | 2019-2024 | Senza |
| Biohaven Pharmaceuticals, INC. | $351.77 | 2020-2021 | |
| Biodelivery Sciences International, INC. | $280.29 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $273.57 | 2022 | |
| Grt US Holding, INC. | $248.00 | 2021-2022 | |
| Vertos Medical, INC. | $147.19 | 2024 | Mild Device Kit |
| Amgen INC. | $145.52 | 2019-2022 | |
| Globus Medical, INC. | $137.44 | 2025 | Senza, Vyrsa V1 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sachida Manocha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.